FOX News: Business
FOXBusiness.com - Breaking news and video. Latest Current News: News, Investing, Technology, Personal Finance, Business Leaders, Travel, On Air, Small Business.
Updated: 12 min 32 sec ago
There is significant turmoil at Alphabet's "other bets" division. Should investors be worried?
The home goods market is already overstocked with outlets, so one more won't matter, though there are trends that do.
After declining sequentially for two quarters in a row, what should investors expect from Model S sales this quarter?
The energy infrastructure company and its MLP Williams Partners are a 2018 story.
The data storage company jumped on a strong earnings report.
Improving its balance sheet after its recent shopping spree, converting stores to boost same-store sales, and consolidating the retail fuels space would go a long way toward increasing Sunoco's stock price.
Could a deal with a major automaker be a good sign for fuel cells in the future?
The offshore oil companys new CEO and CFO recently bought shares.
The cigarette maker has a surprising success story in its operations.
The Chinese classifieds company is feeling the pain of its country's economic slowdown.
Oil prices per barrel differ depending on type and location, which can mean a lot to oil stocks.
Issuing stock when shares are already down more than 75% doesn't sound like the most fiscally responsible thing to do.
The U.S. District Attorney's luck may be changing thanks to a father - son duo who broke the law.
A good earnings report may be masking challenges ahead.
Even though Philip Morris International has faced challenges, there are reasons for optimism.
Cheniere Energy's Management is Finally Talking to Investors, Here Are 4 Things They Want You to Know
Cheniere Energy's most recent conference call was like one giant "under new management" sign.
Agenus and Bellicum Pharmaceuticals are two hidden gems in the high-growth cancer drug space.
Preferred stocks can give you the income you need, and these funds are a great way to invest in them.
With a key patent for Remicade just invalidated and a copycat drug looming, J&J may be due for a haircut.
It’s a problem we hear about every day, but nobody thinks it directly affects them; the national debt.